BCR-ABL1, Minor (p190), Quantitative

Patient: [redacted]
DOB: Not Provided Age: N/A Gender: M
Patient Identifiers: [redacted]
Visit Number (FIN): [redacted]

Client: [redacted]
Physician: [redacted]

ARUP Test Code: 2005016

Collection Date: 09/24/2021
Received in lab: 09/24/2021
Completion Date: 10/05/2021

Patient Result Summary

Result: Detected

***BCR-ABL1/ABL1* Ratio: 0.03914**

BCR-ABL1 fusion transcripts (p190 form) were detected by RT-qPCR. This result has been reviewed and approved by [redacted]

Patient History Results

Collected On	Ratio	Result	Source
09/24/21	0.03914	Detected	Whole Blood
06/15/21	0.04931	Detected	Whole Blood
03/01/21	0.11698	Detected	Whole Blood
12/07/20	0.08567	Detected	Whole Blood
08/20/20	0.13318	Detected	Whole Blood
06/09/20	0.14374	Detected	Whole Blood
03/10/20	0.13917	Detected	Whole Blood
01/07/20	0.17239	Detected	Whole Blood

-See previous individual reports for details on specific test results.
-Historical data is not provided for specimens ordered prior to May 16, 2011.
-Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult this patient's prior charts.

Test Information

Background
This assay quantifies BCR-ABL1 transcripts (e1a2) for diagnosis and ongoing therapeutic monitoring. BCR-ABL1 translocations with BCR breakpoints in the minor breakpoint cluster region result in the p190 fusion protein and are predominantly seen in acute lymphoblastic leukemia (ALL) although they may be present in rare cases of chronic myelogenous leukemia (CML).
Methods
Total RNA is isolated and converted to cDNA and BCR-ABL1 fusions are quantitated by real-time PCR amplification. The primers are designed to detect the minor (p190) BCR-ABL1 breakpoint with a fusion between BCR exon 1 and ABL1 exon 2 (e1a2). Each PCR assay includes a standard curve for BCR-ABL1 and the ABL1 control and a normalized copy number (NCN) is calculated (# BCR-ABL1 cDNA molecules/# ABL1 cDNA molecules).
Limitations
The limit of detection of this assay is 1 BCR-ABL1 positive cell in 125,000 normal cells. The results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.
Compliance
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Chief Medical Officer

END OF CHART